MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 9, 2004; DOI: 10.1124/mol.104.002931


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.002931v1
67/3/703    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Darryl S. Pickering
Bente Vestergaard
Christina Kasper
Bettina Bryde Nielsen
Jeremy R. Greenwood
Michael Gajhede
Arne Schousboe
Jette Sandholm Kastrup
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frandsen, A.
Right arrow Articles by Kastrup, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frandsen, A.
Right arrow Articles by Kastrup, J. S.


Received for publication May 24, 2004.
Revised December 6, 2004.
Accepted for publication December 6, 2004.

Tyr702 is an Important Determinant of Agonist Binding and Domain Closure of the Ligand-Binding Core of GluR2

Anne Frandsen 1, Darryl S. Pickering 1, Bente Vestergaard 1, Christina Kasper 1, Bettina Bryde Nielsen 1, Jeremy R. Greenwood 1, Giuseppe Campiani 2, Caterina Fattorusso 3, Michael Gajhede 1, Arne Schousboe 1, Jette Sandholm Kastrup 1*

1 Danish University of Pharmaceutical Sciences 2 Siena University 3 Napoli University

* Address correspondence to: E-mail: jsk{at}dfuni.dk

Abstract

Ionotropic glutamate receptors mediate most rapid excitatory synaptic transmission in the mammalian central nervous system and their involvement in neurological diseases has stimulated widespread interest in their structure and function. Despite a large number of agonists developed to date, few display selectivity among AMPA-receptor subtypes. The present study provides X-ray structures of the GluR2-selective, partial agonist (S)-2-amino-3-(1,3,5,6,7-pentahydro-2,4-dioxo-cyclopenta[(e]pyrimidin-1-yl) propanoic acid [(S)-CPW399] in complex with the ligand-binding core of GluR2 (GluR2-S1S2J) and with a (Y702F)GluR2-S1S2J mutant. In addition, the structure of the non-selective partial agonist kainate in complex with (Y702F)GluR2-S1S2J was determined. The results show that the selectivity of (S)-CPW399 towards full-length GluR2 relative to GluR3 is reflected in the binding data on the two soluble constructs, allowing the use of (Y702F)GluR2-S1S2J as a model system for studying GluR2/GluR3 selectivity. Structural comparisons suggest that selectivity arises from disruption of a water-mediated network between ligand and receptor. A D1-D2 domain closure occurs upon agonist binding. (S)-CPW399 and kainate induce greater domain closure in the Y702F mutant, indicating that these partial agonists here act in a manner more reminiscent of full agonists. Functionally, both kainate and (S)-CPW399 exhibited higher efficacy at (Y702F)GluR2(Q)i than at wild-type GluR2(Q)i. Whereas an excellent correlation exists between domain closure and efficacy of a range of agonists at full-length GluR2, determined by electrophysiology in Xenopus laevis oocytes, a direct correlation between agonist induced domain closure of (Y702F)GluR2-S1S2J and efficacy at the GluR3 receptor is not observed. While clearly controlling selectivity, mutation of this residue alone is insufficient to explain agonist-induced conformational rearrangements occurring in this variant.


Key words: Glutamate, Structure determinations, Structure-activity relationships and modeling, Receptor binding studies, X-ray crystallography





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics